What is Plus Therapeutics?

Plus Therapeutics is a U.S. clinical- stage pharmaceutical company focused on developing innovative, targeted radiotherapeutics for adults and children with difficult-to-treat cancer.  Their mission?  To solve the toughest challenges in oncology by improving the efficacy, precision, and convenience of radiotherapeutics.

New to Plus Therapeutics is the ReSPECT-GBM Clinical Trial featuring a helpful guide for patients with glioblastoma.  This booklet is a study guide for patients that breaks down the ReSPECT-GBM clinical trial in simple yet educational terms and answers patients’ frequently asked questions. It explains what the clinical trial is, how it works, patient eligibility, risks/benefits, and what happens on each day of the trial which is now enrolling Phase 2 patients with recurrent glioblastoma.

What to expect in this guide

• About the Clinical Trial
• About the Treatment
• Study Qualifications
• Summary of Visits & Screening Tests
• Pre-Treatment & Catheter Placement/Surgery Visits
• Day 1: Treatment Day
• Day 2 & Day 3 Visits
• Day 4, 5, & 6 Visits
• Day 7, 9, & 14 Visits
• Day 28, 56 & End-Of-Study Visits
• Study Follow Up
• Risks and Benefits
• Resources
• Notes

Learn more by visiting Plus Therapeutics Website.

Other helpful links

Link to ReSPECT-GBM Clinical Trial Guide for Patients (also attached): https://www.respect-trials.com/recurrent-glioblastoma-respect-guide/

Link to ReSPECT-GBM Clinical Trial Website: https://www.respect-trials.com/gbm/

Link to ReSPECT’s Recurrent Glioblastoma Patient Guide for Patients: https://www.respect-trials.com/patient-guide-gbm/